U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06899594) titled 'Psilocybin for Methamphetamine Addiction' on Nov. 27, 2024.
Brief Summary: The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and ...